Cargando…
Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies
BACKGROUND: Health-related quality of life (HRQoL) may be markedly impaired in patients with moderate-to-severe psoriasis. OBJECTIVES: Our objectives were to compare improvements in Dermatology Life Quality Index (DLQI) and Psoriasis Symptoms and Signs Diary (PSSD) scores between patients receiving...
Autores principales: | Armstrong, April W., Reich, Kristian, Foley, Peter, Han, Chenglong, Song, Michael, Shen, Yaung-Kaung, You, Yin, Papp, Kim A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513809/ https://www.ncbi.nlm.nih.gov/pubmed/30417277 http://dx.doi.org/10.1007/s40257-018-0396-z |
Ejemplares similares
-
Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2
por: Kim, Byung Soo, et al.
Publicado: (2023) -
Patient‐reported symptoms and signs of moderate‐to‐severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial
por: Papp, K.A., et al.
Publicado: (2018) -
Guselkumab for plaque psoriasis
Publicado: (2019) -
Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
por: Light, Jeremy G, et al.
Publicado: (2021) -
Notes from a Doctor's Diary of His Voyages
Publicado: (1925)